TheProfitWatch

BCAB - BioAtla, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
1.17 -0.3 (-25.64%) 0.0 (0.0%) 0.0 (0.03%) -0.01 (-1.15%) -0.02 (-1.71%) -0.28 (-24.35%) -0.02 (-1.68%) -0.04 (-3.36%)

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.32
Diluted EPS:
-0.32
Basic P/E:
-2.7188
Diluted P/E:
-2.7188
RSI(14) 1m:
56.52
VWAP:
0.87
RVol:

Events

Period Kind Movement Occurred At

Related News